Publications

REFEREED JOURNAL PUBLICATIONS

Managing Director

Aquesta Uropathology

Professor of Pathology

The University of Queensland

School of Medicine

Visiting Medical Officer

Princess Alexandra Hospital

 Secretary

International Society of Urological Pathology

 


 

ARTICLES PUBLISHED IN PROFESSIONAL JOURNALS

163. Lindh C, Delahunt B, Samaratunga H, Yaxley J, Gudjónsdóttir J, Clements M, Lindberg J, Egevad L. A Novel Technique for Biobanking of Large Sections of Radical Prostatectomy Specimens. Histopathology 2017 Sep 7. doi: 10.1111/his.13386. [Epub ahead of print].

162. Egevad L, Cheville J, Evans AJ, Hörnblad J, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, Pan CC, Samaratunga H, Srigley JR, True L, Zhou M, Clements M, Delahunt B; ISUP Pathology Imagebase Expert Panel. Pathology Imagebase – A Reference Image Database for Standardization of Pathology. Histopathology. 2017 Jul 19. doi: 10.1111/his.13313. [Epub ahead of print].

161Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J, Samaratunga H. Clear cell renal cell carcinoma: Validation of WHO/ISUP grading. Histopathology. 2017 Jul 18. doi: 10.1111/his.13311. [Epub ahead of print].

160. Samaratunga H, Delahunt B, Srigley JR, Yaxley J, Johannsen S, Coughlin G, Gianduzzo T, Kua B, Patterson I, Nacey JN, Egevad L. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology 2017 Jun 7. doi: 10.1111/his.13278. [Epub ahead of print].

159. Siriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes AM, Coughlin G, Stricker P.Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.BJU Int 2017 May 26. doi: 10.1111/bju.13919. [Epub ahead of print].

158. Kryza T, Silva LM, Bock N, Fuhrman-Luck RA, Stephens CR, Gao J, Samaratunga H; Australian Prostate Cancer BioResource, Lawrence MG, Hooper JD, Dong Y, Risbridger GP, Clements JA.Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells. Mol Oncol 2017 May 16. doi: 10.1002/1878-0261.12075. [Epub ahead of print].

157. Seipel AH, Whitington T, Delahunt B, Samaratunga H, Mayrhofer M, Wiklund P, Grönberg H, Lindberg J, Egevad L. Genetic Profile of Ductal Adenocarcinoma of the Prostate. Hum Pathol 2017 Apr 27. pii: S0046-8177(17)30133-8. doi: 10.1016/j.humpath.2017.04.015. [Epub ahead of print].

156. Egevad L, Samaratunga H, Delahunt B. Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. Int J Urol 2017; 24(4):286-7.

155. Delahunt B, Grignon DJ, Samaratunga H, Srigley JR, Leite KR, Kristiansen G, Evans AJ, Kench JG, Egevad L.Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Arch Pathol Lab Med 2017; 141(2):182-3.

154. Egevad L, Samaratunga H, Srigley JR, Delahunt B. Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2017; 71(2):e52-e53

153. Delahunt B, Egevad L, Samaratunga H, Varma M, Verrill C, Cheville J, Kristiansen G, Corbishley C, Berney DM. UICC drops the ball in the 8th edition TNM staging of urological cancers.Histopathology2017; 71(1):5-11

152. Egevad L, Samaratunga H, Delahunt B. Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology. 2017 Feb 17. doi: 10.1111/iju.13305. [Epub ahead of print]

151. Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L. The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012. British Journal of Urology International.2017;119(1):50-56.

150. Delahunt B, Grignon DJ, Samaratunga H, Srigley JR, Leite KR, Kristiansen G, Evans AJ, Kench JG, Egevad L. Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology & Laboratory Medicine. 2017;141(2):182-183

149. Egevad L, Samaratunga H, Srigley JR, Delahunt B.Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol. 2017;71(2):e52-e53.

148. Roberts MJ, Richards RS, Chow CW, Doi SA, Schirra HJ, Buck M, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers. Prostate International. 2016;4(3):97-102.

147. Samaratunga H, Delahunt B, Yaxley J, Srigley JR, Egevad L. From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scandinavian Journal of Urology. 2016;50(5):325-329.

146 Egevad L, Samaratunga H, Srigley JR, Delahunt B, Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason Grade. British Journal of Urology International. 2016;118(3). E1-2.

145. Srigley JR, Delahunt B, Egevad L, Samaratunga H, Yaxley J, Evans AJ. One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal 2016;10 (9-10): 339-341.

144. Egevad L, Samaratunga H, Srigley JR, Delahunt B. In Regard to Zietman et al. Int J Radiat Oncol Biol Phys. 2016 1;96(5):1126-1127.

143. Egevad L, Samaratunga H, Srigley JR, Delahunt B. New Gleason grading system: Statement from the editors of 6 journals. Urol Oncol. 2016;34(11):479-480.

142. Egevad L, Samaratunga H, Srigley JR, Delahunt B. Reply by the Authors. Urology. 2016;96:179-180.

141. Egevad L, Samaratunga H, Srigley JR, Delahunt B Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade: A. Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr. Journal of Urology 2016;195: 1723. J Urol. 2016;196(4):1321-3

140. Yaxley JW, Lah K, Yaxley JP, Gardiner RA, Samaratunga H, MacKean J. Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. British Journal of Urology International. 2016 Sep 15. doi: 10.1111/bju.13659. [Epub ahead of print].

139. Rhee H, Ng KL, Tse BW, Yeh MC, Russell PJ, Nelson C, Thomas P, Samaratunga H, Vela I, Gobe G, Wood S. Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology. 2016;48(6):613-616.

138. Yaxley JW, Coughlin GD, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Dunglison N, Carter R, Williams S, Payton DJ, Perry-Keene J, Lavin MF, Gardiner RA. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016 : 10;388(10049):1057-1066.

137, Roberts MJ, Yaxley JW, Coughlin GD, Gianduzzo TR, Esler RC, Dunglison NT, Chambers SK, Medcraft RJ, Chow CW, Schirra HJ, Richards RS, Kienzle N, Lu M, Brereton I, Samaratunga H, Perry-Keene J, Payton D, Oyama C, Doi SA, Lavin MF, Gardiner RA. Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol. Contemporary Clinical Trials. 2016; 50:16-20.

136. Seipel AH, Delahunt B, Samaratunga H, Egevad L. Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology. 2016;48(5):398-405.

135. Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer – An ISUP consensus on contemporary grading. Acta Pathologica Microbiologica, et Immunologica Scandinavica. 2016;124(6):433-435.

134. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Reply: Gleason and Fuhrman no longer make the grade. Histopathology. 2016;69(2):341-2.

133. Delahunt B, Egevad L, Grignon DJ, Srigley JR, Samaratunga H. Prostate cancer grading: recent developments and future directions. British Journal of Urology International 2016;117 Suppl 4:7-8.

132. Egevad L, Delahunt B, Evans AJ, Grignon DJ, Kench JG, Kristiansen G, Leite KR, Samaratunga H, Srigley JR. International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. American Journal of Surgical Pathology. 2016; 40(6):858-861.

131. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Gleason and Fuhrman no longer make the grade. Histopathology. 2016;68(4):475-481.

130. Ng KL, Morais C, Bernard A, Saunders N, Samaratunga H, Gobe G, Wood S. A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma. Journal of Clinical Pathology. 2016;69(8):661-671.

129. Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Compérat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, Netto GJ, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ. Gleason Grade 4 Prostate Adenocarcinoma Patterns: An Inter-observer Agreement Study among Genitourinary Pathologists. Histopathology. 2016;69(3):441-449.

128. Gobe GC, Ng KL, Small DM, Vesey DA, Johnson DW, Samaratunga H, Kimberley O, Wood S, Barclay JL, Rajandram R, Li L, Morais C. Decreased Apoptosis Repressor with Caspase Recruitment Domain Confers Resistance to Sunitinib in Renal Cell Carcinoma through Alternate Angiogenesis Pathways. Biochemical and biophysical research communications. 2016; 22;473(1):47-53.

127. Seipel AH, Samaratunga H, Delahunt B, Wiklund P, Clements M, Egevad L. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study. Acta Pathologica, Microbiologica, et Immunologica Scandinavica.. 2016;124(4):263-270.

126. Egevad L, Delahunt B, Samaratunga H, Srigley JR. Utility of Reporting the Percentage of High-grade Prostate Cancer. European Urology. 2016 ;69(4):599-600.

125. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee including Samaratunga H. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. American Journal of Surgical Pathology. 2016;40(2):244-252.

124. Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology 2016;11(3):345-351.

123. Samaratunga H, Delahunt B, Egevad L, Adamson M, Hussey D, Malone G, Hoyle K, Nathan T, Kerle D, Fergusson P, Nacey JN. Pleomorphic Giant Cell Carcinoma of the Urinary Bladder: An Extreme Form of Tumour De-differentiation. Histopathology. 2016;68(4):533-540.

122. Samaratunga H, Delahunt B. Mesenchymal tumors of adult kidney. Seminars in  Diagnostic Pathology. 2015;32(2):160-171.

121. Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015;47(1):1-3.

120. Matsika A, Srinivasan B, Day C, Mader SA, Kiernan DM, Broomfield A, Fu J, Hooper JD, Kench JG, Samaratunga H. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2.  Pathology. 2015; 47(7):622-628.

119. Samaratunga H, Delahunt B, Gianduzzo T, Coughlin G, Duffy D, LeFevre I, Johannsen S, Egevad L, Yaxley J. The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology. 2015;47(6):515-519.

 118. Scott S, Samaratunga H, Chabert C, Breckenridge M, Gianduzzo T. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis. British Journal of Urology International. 2015;116 Suppl 3:26-30.

117. Roberts MJ, Chow CW, Schirra HJ, Richards R, Buck M, Selth LA, Doi SA, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Prostate. 2015 1;75(5):539-549.

116. Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons’ Section of Oncology.; UK ProtecT Study Collaborators inc Samaratunga H; PRACTICAL Consortium. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer epidemiology, biomarkers & prevention. 2015;24(7):1121-1129.

115. Srigley JR, Delahunt B, Egevad L, Samaratunga H, Evans AJ. Optimising pre-analytical factors affecting quality of prostate biopsies: the case for site specific labelling and single core submission. Pathology. 2014;46(7):579-580.

114. Rioux-Leclercq N, Algaba F, Amin M, Argani P, Billis A, Bonsib S, Cheng L, Cheville J, Eble J, Egevad L, Epstein J, Grignon D, Hes O, Humphrey P, Maggi-Galluzzi C,  Martignoni G, McKenney J, Merino M, Moch H, Montironu R, Netto G, Reuter V, Samaratunga H, Shen S, Srigley J, Tamboli P, Tan P, Tickoo S, Trpkov K, Zhou M, Delahunt B, Comperat E. Les tumeurs rénales : recommandations de la conférence de consensus de l’International Society of Urologic Pathology (ISUP) Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations. Annales De Pathologie. 2014;34(6):448-461.

113. Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archives. 2014;465(6):623-628.

112. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond E. The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists and the Prostate Cancer Foundation. Archives of Pathology & Laboratory Medicine. 2014;138(10):1387-405.

111. Delahunt B, Samaratunga H, Martignoni G, Srigley JR, Evans AJ, Brunelli M. Percutaneous Renal Tumour Biopsy. Histopathology. 2014;65(3):295-308.

110. Samaratunga H, Gianduzzo T, Delahunt B. The ISUP system of staging, grading and classification of renal cell neoplasia. Journal of Kidney Cancer and VHL. 2014  1:26-39.

109. Ng KL, Rajandram R, Morais C, Yap NY, Samaratunga H, Gobe GC and Wood ST. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? Journal of Clinical Pathology2014;67(2):97-104.

108. Gardiner RA, Chambers SK, Williams SG, Yaxley J, Samaratunga H, Frydenberg M  Prostate Cancer – Part One: Detection. In : De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. 2014 Jun 2.

107. Perry-Keene J, Ferguson P, Samaratunga H, Nacey JN, Delahunt B. Effective maybe, but is it cost-effective? A reply. Histopathology. 2014;65(5):729-730.

106. Klopfer K, Delahunt B, Adamson M, Samaratunga H. Value of Uroplakin III in Distinguishing Variants of Primary Bladder Urothelial Carcinoma from Malignancy Metastatic to the Urinary Bladder. Anticancer Research. 2014;34(11):6779-6784.

105. Seipel AH, Samaratunga H, Delahunt B, Wiklund F, Wiklund P, Lindberg J, Grönberg H, Egevad L. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Archives 2014;465(5):559-565.

104. Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, Humphrey PA, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S and Egevad L. Diagnostic Criteria for Ductal Adenocarcinoma of the Prostate. Interobserver Variability among 20 Expert Uropathologists. Histopathology. 2014;65(2):216-227.

103. Samaratunga H, Delahunt B, Yaxley J, Perry-Keene J, Lamb DS, Srigley JR, Egevad L and Nacey JN. Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. Pathology. 2014;46(1):11-14.

102. Gardiner RA, Coughlin GD, Yaxley JW, Dunglison NT, Occhipinti S, Younie SJ, Carter RC, Williams SG, Medcraft RJ, Samaratunga HM, Perry-Keene JL, Payton DJ, Lavin MF and Chambers SK. A progress report on a prospective randomised trial of open and robotic prostatectomy. European Urology. 2014;65(3):512-515.

101. Perry-Keene J, Ferguson P, Samaratunga H, Nacey JN and Delahunt B. Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases. Histopathology. 2014;65(5):729-730.

100. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR and the members of the ISUP Renal Tumor Panel. Handling and Staging of Renal Cell Carcinoma: The International Society of Urological Pathology Consensus (ISUP) Conference Recommendations. American Journal of Surgical Pathology. 2013; 37(10):1505-1517.

99. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H and the ISUP Renal Tumor Panel including Samaratunga H. Renal tumors: diagnostic and prognostic biomarkers. American Journal of Surgical Pathology. 2013;37(10):1518-1531.

98. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel including Samaratunga H. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. American Journal of Surgical Pathology. 2013;37(10):1490-1504.

97. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P and the ISUP Renal Tumor Panel including Samaratunga H. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology. 2013;37(10):1469-1489.

96. Compérat E, Camparo P, Srigley J, Delahunt B, Egevad L and ISUP Consensus Working Group inc. Samaratunga H International Society of Urological Pathology (ISUP) Consensus Conference on handling and H of radical prostatectomy specimens]. Annales De Pathologie. 2013;33(3):155-161.

95.   Samaratunga H, Martignoni G, Egevad L and Delahunt B. Premalignant lesions of the urinary bladder. Pathology. 2013;45(3):243-50.

94. Samaratunga H and Delahunt B. Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology. 2012;44(5):407-18.

93. Delahunt B, Miller RJ, Srigley JR, Evans AJ and Samaratunga H. Gleason grading: past, present and future. Histopathology. 2012;60(1):75-86.

92. Samaratunga H, Samaratunga D, Dunglison N, Perry-Keene J, Nicklin J and Delahunt B. Alpha-fetoprotein-producing Carcinoma of the Renal Pelvis Exhibiting Hepatoid and Urothelial Differentiation. Anticancer Research. 2012;32(11):4987-4991.

91. Bennett NC, Hooper JD, Lambie D, Lee CS, Yang T, Vesey DA, Samaratunga H, Johnson DW and Gobe GC. Evidence for steroidogenic potential in human prostate cell lines and tissues. American Journal of Pathology. 2012;181(3):1078-1087.

90. Lose F, Srinivasan S, O’Mara T, Marquart L, Chambers S, Gardiner RA, Aitken JF; the Australian Prostate Cancer BioResource, Collaborators inc Samaratunga H Spurdle AB, Batra J and Clements JA. Genetic Association of the KLK4 Locus with Risk of Prostate Cancer. PLoS One. 2012;7(9):e44520.

89. Ranaweera M, Samaratunga H, Duffy D, Klopfer K, Brunelli M, Martignoni G, Delahunt B. Tertiary Gleason pattern 5 on needle biopsy predicts greater tumour volume on radical prostatectomy. Pathology. 2011;43(7):693-696.

88. Delahunt B, Sika-Paotonu D, Bethwaite PB, William Jordan T, Magi-Galluzzi C, Zhou M, Samaratunga H and Srigley JR. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. American Journal of Surgical Pathology. 2011;35(8):1134-1139.

87. Kench JG, Clouston DR, Delprado W, Eade T, Ellis D, Horvath LG, Samaratunga H, Stahl J, Stapleton AM, Egevad L, Srigley JR Delahunt B. Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology. 2011;43(5):410-419.

86. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B and Egevad L; The ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology. 2011;24(1):6-15.

85. Egevad L, Srigley JRDelahunt BAmin, MBerney DMBillis ACheng LEpstein JEvans AGrignon DHumphrey PMagi-Galluzzi CMontironi RSamaratunga HTan PHTrue LVan Der Kwast TWheeler T International society of urological pathology consensus conference on handling and staging of radical prostatectomy specimens Advances in Anatomic Pathology. 2011; 18: 301-305

84. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B; the ISUP Prostate Cancer Group (Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern Pathology. 2011;24(1):16-25.

83. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI. The ISUP Prostate Cancer Group (Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Modern Pathology. 2011;24(1):48-57.

82. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA, the ISUP Prostate Cancer Group (Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Modern Pathology. 2011;24(1):26-38.

81. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR; the ISUP Prostate Cancer Group(Inc. Samaratunga H). International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology. 2011;24(1):39-47.

80.Compérat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaïd I, Cussenot O and Samaratunga H. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology. 2010;42(7):650-654.

79. Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA Marshall VR, Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H,  Clements JA, Risbridger GP, Sutherland RL, Tilley WD; and Horsfall DJ for the Australian Prostate Cancer BioResource Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer epidemiology, biomarkers & prevention. 2010;19(7):1755-1765.

78. Delahunt B, Lamb DS, Srigley JR, Murray JD, Wilcox C, Samaratunga H, Atkinson C, Spry NA, Joseph D and  Denham JW. Gleason scoring: A comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point. Pathology. 2010;42(4):339-343.

77. Samaratunga H, Samaratunga D, Perry-Keene J, Adamson M, Yaxley J and Delahunt B. Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration. Pathology. 2010 42(4):330-333.

76. Whitbread AK, Veveris-Lowe TL, Dong Y, Tan OL, Gardiner R, Samaratunga HM, Nicol DL and Clements JA. Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry. 2010;391(4):461-466.

75. Gobbo S, Eble JN, Delahunt B, Grignon DJ, Samaratunga H, Martignoni G, Zhang S, Wang M, Brunelli M, Cossu-Rocca P, Cheng L. Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical and cytogenetic profiles American Journal of Surgical Pathology. 2010;34(5):620-626.

74. Aydin H, Zhang J, Samaratunga H, Tan N, Magi-Galluzzi C, Klein E, Jones JS and Zhou M. Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. British Journal of Urology International. 2010;105(4):476-480.

73. Samaratunga H, Duffy D, Yaxley J and Delahunt B Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Human Pathology. 2010;41(2):281-285.

72. Samaratunga H, Epstein JI. Genitourinary pathology in the new millennium. Pathology. 2010;42(4):317-318.

71. Clarke RA, Zhao Z, Guo AY, Roper K, Teng L, Fang ZM, Samaratunga H, Lavin MF and Gardiner RA New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One. 2009;4(3):e4995.

70. Samaratunga H and Delahunt B.  Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol. 2008;30(4):237-246.

69. Samaratunga H and Epstein JI. What is the molecular pathology of low-risk prostate cancer? World J Urol. 2008;26(5):431-436.

68. Samaratunga H and Fitzpatrick P.  Cellular angiofibroma of the scrotum. Pathology. 2008;40(3):330-333.

67. Cheng L,Gobbo S, Eccher A, Eble J, Delahunt B, Grignon D, Samaratunga H et al. Hybrid tumors in renal oncocytosis: the missing link between oncocytoma and chromophobe renal cell carcinoma? Virchows Archives 2008; 452: S12 -S13.

66. Ramsay AJ, Reid JC, Adams MN, Samaratunga H, Dong Y, Clements JA and Hooper JD. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological Chemistry. 2008;389(6):653-668.

65. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF and Gardiner RA. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. British Journal of Cancer. 2008 ;5;99(3):491-501.

64. Willems AJ, Dawson S, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ; kConFab Investigators..Loss of heterozygosity at the BRCA2 locus detected by Multiplex ligation-Dependent Probe Amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clinical Cancer Research. 2008 15;14(10):2953-2961.

63. Dong Y, Matigian N, Harvey TJ, Samaratunga H, Hooper JD and Clements JA. Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biological Chemistry. 2008;389(2):99-109.

62. Kaushal A, Myers SA, Dong Y, Lai J, Tan OL, Bui LT, Hunt ML, Digby MR, Samaratunga H, Gardiner RA, Clements JA and Hooper JD. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus. Prostate. 2008 1;68(4):381-399.

61. Samaratunga H and Letizia B. Prostatic ductal adenocarcinoma presenting as a small prostatic urethra polyp; a clinicopathological analysis of 8 cases of a lesion with the potential to be misdiagnosed as a benign prostatic urethra polyp. Pathology. 2007;39(5):476-481.

60. Samaratunga H, Yaxley J, Kerr K, McClymont K and Duffy D. The significance of a minute focus of adenocarcinoma on prostate needle biopsy. Urology. 2007; 70(2): 299-302.

59. Samaratunga H. Editorial comment on: Inflammatory atrophy on prostate needle biopsies: Is there topographical relationship to cancer.  International Brazilian Journal of Urology2007; 33: 363.

58. Samaratunga H, Gardiner RA, Yaxley J and Brown I. Atypical prostatic glandular proliferations on needle biopsy: Diagnostic implications, use of immunohistochemistry and clinical significance. Analytical and Quantitative Cytology and Histology. 2006;28(2):104-110.

57. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A and Lucia MS. A working group classification of focal prostate atrophy lesions. American Journal of Surgical Pathology. 2006;30(10):1281-1291.

56. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL and the ISUP Grading Committee (Inc. Samaratunga H) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology. 2005; 29: 1228-1242.

55. Gardiner RA, Landers K, Burger MJ et al inc. Samaratunga H. Claudin 4: A new therapeutic target for prostate cancer. British Journal of Urology International. 2005; 95:1.

54. Dong Y, Bui LT, Odorico DM, Tan OL, Myers SA, Samaratunga H, Gardiner RA, Clements JA. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.  Endocrine Related Cancer. 2005;12(4):875-889.

53. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF and Gardiner RA. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005 10;114(6):950-956.

52. Samaratunga H, Fairweather P and Purdie D. Significance of stromal reaction patterns in invasive urothelial carcinoma. American Journal of Clinical Pathology. 2005;123(6):851-857.

51. Samaratunga H and Khoo K.  Micropapillary urothelial carcinoma of the urinary bladder: Histopathology. 2004;45(1):55-64.

50. McCulloch DR, Akl P, Samaratunga H , Herington AC and Odorico DM. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clinical Cancer Research. 2004 1;10(1 Pt 1):314-323.

49. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, Samaratunga H, Clements JA.  Human Kallikrein 4 (KLK 4) is highly expressed in serous ovarian carcinomas.  Clinical Cancer Research. 2003;9(5):1710-1720.

48. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF and Gardiner RA.  Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer: International Journal of Cancer. 2002; 10;100(2):228-237.

47. Samaratunga H, Makarov DV and Epstein JI.  Comparison of WHO/ISUP and WHO Classification of non-invasive papillary urothelial neoplasms for risk of progression: Urology. 2002;60(2):315-319.

46. Epstein JI, Makarov DV and Samaratunga H. Comparison of WHO/ISUP and WHO Classification of non-invasive papillary urothelial neoplasms (pTa) for risk of progression. Journal of Urology. 2002; 16: 190-191.

45. Samaratunga H, Weedon D, Musgrave N and McCallum N. Atypical Presentation of Herpes Simplex (Chronic Hypertrophic Herpes) in a patient with HIV infection. Pathology. 2001; 33:530-533.

44. Samaratunga H, Clarke B, Owen L, Bryson G and Swanson C.  Phyllodes tumours of the breast: correlation of nucleolar organizer regions with histopathological malignancy grading, flow cytometric.  DNA analysis and clinical outcomePathology International. 2001;51(11):866-873.

43. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM and McManus ME.  Localization of N-acetyl Transferases NATI and NAT2 in human tissue.  Toxicological Sciences. 2000;54(1):19-29.

42. Samaratunga H, Spork MR and Cooritz D.  Sclerosing sertoli cell  of tumor of testis  Journal of Urological Pathology. 2000;12: 39-50.

41. Samaratunga H and Williamson R.  Metastatic foamy gland carcinoma of prostate.  Journal of Urological Pathology. 2000; 12: 53-54.

40. Horwood KR, Samaratunga H Primary vaginal non-Hodgkin’s lymphoma after radiotherapy for Hodgkin’s disease. Australian and New Zealand journal of medicine. 2000;30(3):404-405.

39. Samaratunga H.  Cervical adenoid basal epithelioma.  :  The American journal of surgical pathology. 1999; 23: 1308-1309.

38. Clements JA, Rohde P, Allen V, Hyland V, Samaratunga ML, Tilley W, Lavin M and Gardiner RA.  Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. Journal of Urology. 1999; 161: 1337-1343.

37.  Kotlovsky A, Sillar D, Samaratunga M and Gardiner RA.  Evaluation of myectonized partial thickness ileum in experimental bladder augmentation:  Australian and New Zealand journal of Surgery. 1998; 68: 587-591.

36. Samaratunga H and Williamson R.  Metastatic foamy gland carcinoma of the prostate. A potential diagnostic pitfall.  Journal of Urological Pathology. 1998; 9:155-161.

35.  Teng HS, Hardie IR, Samaratunga MLTH and Gardiner RA.  Experimental pyeloureterectomy and calyceal neck transection with autotransplantation and bladder advancement. British Journal of Urology. 1998; 82: 877-881.

34. McCrystal D, O’Loughlin B and Samaratunga H.  Mesenteric panniculitis; a mimic of malignancy. Australian and New Zealand Journal of Surgery. 1998 68: 237-239.

 33. Samaratunga H, Searle JW and Hudson N.  Non-rabies Lyssavirus human encephalitis from fruit bats.  Australian bat Lyssavirus (Pteropid Lyssavirus) infection.  Neuropathology and Applied Neurobiology. 1998; 24: 331-335.

32. Hooper PT, Lunt RA, Gould A, Samaratunga H, Hyatt AD, Westbury HA, Gleeson LJ and Murray PK.  A new Lyssavirus – The first endemic Rabies-related virus recognised in Australia.  Bulletin de L’Institute Pasteur; Research in Infectious Diseases . 1997; 95: 209-218.

31. Samaratunga H and Singh M. Distribution pattern of basal cells detected by Cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma.  American Journal of Surgical Pathology. 1997; 21(4): 435-440.

30. Sillar DB, Samaratunga H, O’Brien M, Kotlovsky A, Mundy AR and Gardiner RA. Intussuscepted partial thickness ileal valve (IPI-valve) incontinent diversion diversion. European Urology. 1997; 31: 102-107.

29. Samaratunga H, Perry-Keene D and Apel RA. Primary lymphoma of pituitary gland. Endocrine Pathology 1997; 8: 335-341.

28. Gardiner RA, Samaratunga MLTH, Rhoder P, Clements JA, Hyland V and Lavin MF.  Malignant cytological washings from radical prostatectomy specimens; a possible mechanism for local recurrence of prostate carcinoma following surgical treatment of organ confined disease. Journal of Urology 1997; 158: 889.

27. Gardiner RA, Samaratunga MLTH, Gwynne RA, Clague A, Seymore GJ and Lavin MF. Abnormal prostatic cells in ejaculates from men with prostatic cancer – a preliminary report:  British Journal of Urology. 1996; 78: 414-418.

26. Kotlovsky A, Samaratunga MLTH and Gardiner RA.  Myectomised partial thickness bowel in urinary reconstruction.  Australian and New Zealand journal of Surgery. 1996; 66: 390.

25. Samaratunga H, Searle J and O’Loughlin B. Intravascular fasciitis:  A case report and review of the literature.  Pathology. 1996; 28: 8-11.

24. Samaratunga H, Searle J and O’Loughlin B. Nodular fasciitis and related pseudosarcomatous proliferative lesions of skin and soft tissue. Australian and New Zealand Journal of Surgery. 1996; 66: 22-25.

23. Calvert ML, Robertson I and Samaratunga H. Mango dermatitis: allergic contact dermatitis to Mangifern indica.  Australian Journal of Dermatology. 1996 37: 59-60.

22. Samaratunga H. Carcinoma in mesonephric remnants: American Journal of Surgical Pathology.1995; 19: 1218-1219.

21. . Devine PL, Walsh MD, McGuckin MA, Quin RJ, Hohn BG, Clague A, Samaratunga H. Prostate – specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. International Journal of Biological Markers. 1995;10: 221-225.

20. Singh M, Samaratunga H, Wright C and Guandalini I. Prostatic carcinoma metastatic to the testis simulating intratubular germ cell neoplasia. British Journal of Urology. 1995; 75: 803-804.

19. Samaratunga H, Kanowski P, O’Loughlin B, Walker N and Searle J. Adenocarcinoma of the rete testis with intratubular invasion of the testis. Journal of Urological Pathology. 1994; 2: 291-300.

18. Walsh MD, Hohn BG, Thong W, Devine PL, Gardiner RA, Samaratunga MLTH and McGuckin MA. Mucin expression by transitional cell carcinomas of the bladder. British Journal of Urology. 1994; 73: 256-262.

17. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga MLTH, Seymore GJ and Lavin MF. Immunohistologic expression of P53 in primary PT1 transitional cell bladder cancer does not relate to tumour progression.  British Journal of Urology. 1994; 73: 526-532.

16. Samaratunga H, Beresford A and Davison A. Squamous-cell carcinoma in situ involving mesoneoplasic remnants – A potential diagnostic pitfall:  The American journal of surgical pathology.1994;18: 1265-1269.

15. Samaratunga H, Searle J, Cominos D and LeFevre I. Cerebral metastasis of an atrial myxoma mimicking an epithelioid hemangioendothelioma: American Journal of Surgical Pathology. 1994; 18: 107-111.

14. Samaratunga H, Cox N and Wright RG. Human papilloma virus DNA in glandular lesions of the uterine cervix.  Journal of clinical pathology. 1993;46(8):718-721.

13. Apel R and Samaratunga H. Lymph node pseudotumor – American Journal of Surgical Pathology 1993; 17: 91-93.

12. Samaratunga H, Hohn BG, Walsh M, Gardiner RA, Devine PL and McGuckin MA.Mucin inclusions in urothelial carcinomas. Human Pathology. 1993; 24(8): 929-930.

11. Gardiner RA, Samaratunga MLTH, Walsh MD, Seymore GL and Lavin MF. An Immunohistochemical Demonstration of C-erb-B2 Oncoprotein Expression in Primary Urothelial Bladder Cancer. Urology Research. 1992; 20: 117-120.

10. Wright RG, Samaratunga MLTH and Jaworski R. Absence of Human Papilloma Virus in Cervical Adenocarcinoma. Journal of Clinical Pathology 1992; 45: 271.

9. Samaratunga H and Wright G. Value of Fine Needle Aspiration Biopsy Cytology in the Diagnosis of Discrete Hepatic Lesions Suspicious for Malignancy. Australian and New Zealand journal of  Surgery. 1992; 62: 540-544.

8. Samaratunga H, Strutton G, Wright RG and Hill B. Squamous cell carcinoma arising in a case of vulvitis granulomatosa or vulval variant of Melkersson-Rosenthal syndrome. Gynecologic Oncology. 1991; 41: 263-269.

7. Nicklin JL, Wright RG, Bell JR, Samaratunga MLTH, Cox NC and Ward BG. A Clinicopathologic Study of Adenocarcinoma in Situ of the Cervix.  The influence of cervical HPV infection and other factors, and the role of conservative surgery.  Australian and New Zealand journal of  Obstetrics and Gynaecology. 1991; 31(2):179-183.

6. Gardiner RA and Samaratunga MLTH. Application of the Invaginated Sleeve Technique to form a Continent Ileal Urostomy.  British Journal of Urology 1990; 65: 457-461.

5.  Gardiner RA, Mills G, Rivory L and Samaratunga MLTH. Evaluation of a Bladder Advancement Extension Graft Technique. British Journal of Urology. 1990 66: 606-612.

4. Samaratunga H and Cox N. Evaluation of an In Situ Hybridization Kit for the Diagnosis of Cytomegalovirus Infection: Australian Journal of Medical Laboratory Science. 1990; 11: 11-14

3. Gardiner RA, Samaratunga MLTH. Development of the Invaginated Sleeve Technique for Continent Cystostomies in Dogs.  British Journal of Urology 1989; 63: 276-280.

2. Gardiner RA, Samaratunga MLTH. Flap valve cystostomy using an invaginated sleeve of mucosa, lamina propria and superficial muscle. British Journal of Urology. 1988; 62: 473-475.

1. Faoagali JL, DeBuse P, Strutton GM, Samaratunga H. A Case of Rabies:  The Medical Journal of Australia 1988; 149: 11-12.

 

BOOK CHAPTERS 

19. Egevad L, Epstein JI, Hameed O, Humphrey PA, Samaratunga H.  Ductal adenocarcinoma. Tumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Moch H, Humphrey P, Ulbright T, Reuter V. 4th edition. 2016. IARC Press.  Zurich. ISBN 978-92-832-2437-2.

18. Humphrey PA, Amin MB, Berney DM, Billis A, Cao D, Cheng L, Delahunt B, Egevad L, Epstein JI, Fine SW, Grignon DJ, Kristiansen G, Lopez-Beltran A, Magi-Galuzzi C, Netto GJ, Rubin MA, Samaratunga H, Srigley JR, True LD, Tsuzuki T, Van der Kwast T. Acinar adenocarcinoma. Tumours of the Urinary System and Male Genital Organs – World Health Organization  Classification of Tumors Editors: Moch H, Humphrey P, Ulbright T, Reuter V. 4th edition.  IARC Press. Zurich. ISBN 978-92-832-2437-2.

17. Delahunt B, Samaratunga H. Chapter 4. Pathology of the Renal Pelvis and Ureter. Urological Pathology. Editors: Amin MB, Grignon DJ, Srigley JR, Eble JN,. 1st Edition. 2014. Lippincott, Williams and Wilkins: Philadelphia. ISBN 978-0781782814.

16. Samaratunga H. Urothelial carcinoma with syncytiotrophoblastic giant cells. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012. Elsevier Philadelphia. ISBN:978-1-4377-2523-0.

15. Samaratunga H. Metastatic carcinoma to the bladder. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition. 2012.  Elsevier Philadelphia.  ISBN:978-1-4377-2523-0.

14. Samaratunga H. Squamous cell carcinoma, verrucous of penis. High Yield Uropathology.  Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012.  Elsevier Philadelphia. ISBN:978-1-4377-2523-0.

13. Samaratunga H. Urothelial carcinoma, micropapillary variant. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012.  Elsevier Philadelphia.  ISBN:978-1-4377-2523-0.

12. Samaratunga H. Chemotherapy-induced cystitis. High Yield Uropathology.  Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012. Elsevier Philadelphia. ISBN:978-1-4377-2523-0.

11. Samaratunga H. Cryptorchidism. High Yield Uropathology. Editors:  Zhou M, Netto G, and Epstein JI. 1st Edition 2012. Elsevier Philadelphia ISBN:978-1-4377-2523-0.

10. Samaratunga H. Juvenile granulosa cell tumour. Editors: Zhou M, Netto G, and Epstein JI. Editors. 1st Edition 2012. Elsevier Philadelphia ISBN:978-1-4377-2523-0.

9. Samaratunga H. Aggressive angiomyxoma. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

8. Samaratunga H. Collecting duct carcinoma. High Yield Uropathology.  Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

7. Samaratunga H. Congenital mesoblastic nephroma. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

6. Samaratunga H. Post-atrophy hyperplasia. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012 Elsevier Philadelphia ISBN:978-1-4377-2523-0.

5. Samaratunga H. Prostatic carcinoma- foamy gland variant. High Yield Uropathology. Editors: Zhou M, Netto G, and Epstein JI. 1st Edition 2012.  Elsevier Philadelphia ISBN:978-1-4377-2523-0.

4. Samaratunga H. Ductal adenocarcinoma. High Yield Uropathology. Editors:  Zhou M, Netto G, and Epstein JI. 1st Edition 2012. Elsevier Philadelphia ISBN:978-1-4377-2523-0.

3. Epstein JI, Algaba F, Allsbrook Jr WC, Bastacky S, Boccon-Gibod L, DeMarzo AM, Egevad L, Furusato M, Hamper UM, Helpap B, Humphrey PA, Icskowski KA, Lopez-Beltran A, Montironi R, Rubin MA, Sakr WA, Samaratunga H & Parkin DM.  Acinar adenocarcinoma. Tumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 3rd edition. 2004. IARC Press.  Lyon. ISBN 92-832-21424.

2. Yang XJ, Cheng L, Helpap B & Samaratunga H.  Ductal adenocarcinoma. Tumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 3rd edition. 2004. IARC Press.  Lyon. ISBN 92-832-21424,

1. Iczkowski KA, Samaratunga HM, Cheng L, Helpap B, Parkinson MC, Yang XJ & Sesterhenn I. Tumours of the seminal vesicles. Tumours of the Urinary System and Male Genital Organs – World Health Organization Classification of Tumors. Editors: Eble JN, Sauter G, Epstein JI, Sesterhenn I. 3rd edition. 2004. IARC Press.  Lyon.ISBN 92-832-21424.

BOOKS

7. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Ellis D, Horvath L, Samaratunga H, Stahl J and Stapleton A.  Prostate Cancer (Core/Needle Biopsy) Structured Reporting Protocol. 1st Edition. 2014. Royal College of Pathologists of Australasia, Sydney, Australia. ISBN, 978-1-74187-474-7.

6. Samaratunga H, Clouston D, Delahunt B, Delprado W, Grimes D, Kench J, Perry   Keane J and Yaxley J.  Urinary Bladder Carcinoma Structured Reporting Protocol (Radical Cystectomy, Partial Cystectomy, Cystoprostatectomy). 1st Edition. 2012 Royal College of Pathologists of Australasia. Sydney, Australia. ISBN 978-1-74187-704-5.

5. Clouston D, Charles A, Delahunt B, Davis I, Delprado W, Eade T, Kench J, Lawrentschuk  N and Samaratunga H.  Testicular Tumours Structured Reporting Protocol. 1st Edition. 2011. Royal College of Pathologists of Australasia. Sydney, Australia. ISBN 978-1-74187-702-1.

4. Delahunt B, Charles A, Clouston D, Delprado W, O’Donnell A, Eade T, Kench J, Lau H and Samaratunga H.  Renal Parenchymal Malignancy (Renal Cell Carcinoma) Structured Reporting Protocol. 1st Edition. 2011. Royal College of Pathologists of Australasia.Sydney, Australia. ISBN 978-1-74187-655-0.

3. Delahunt B, Galletly DC, Samaratunga H, Koleda CB, Bethwaite PB. Manual of the Use and Interpretation of Pathology. 5th Edition. 2009. Royal College of Pathologists of Australasia, Sydney, Australia. ISSN 1449-8219.

2. Kench J, Clouston D, Delahunt B, Delprado W, Eade T, Ellis D, Horvath L, Kneebone A, Samaratunga H, Stahl J and Stapleton A.  Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol.  1st Edition. 2010. Royal College of Pathologists of Australasia, Sydney, Australia ISBN 978-1-74187 – 462-4.

1. Samaratunga H, Epstein JI (Editors) Prostate Pathology: International Academy ofPathology Slide Seminar Series. 1st Edition 2004; Knowledge Books, Australia; ISBN 1920824 91-x.